Biohaven (BHVN) Resumen de Acciones

Análisis fundamental de BHVN
Puntuación del snowflake
Valoración	0/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	3/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 67.15%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Tiene menos de 1 año de cash runway

Los accionistas han sido diluidos sustancialmente en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 1 riesgos adicionales

BHVN Community Fair Values

Create Narrative

See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW496,749 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

496,749 investors already sharing narratives

View all narratives

Competidores de Biohaven Ltd.

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Biohaven
Precios históricos de las acciones
Precio actual de la acción	US$15.96
Máximo en las últimas 52 semanas	US$18.57
Mínimo de 52 semanas	US$7.48
Beta	3.14
Cambio en 1 mes	47.78%
Variación en 3 meses	74.43%
Cambio de 1 año	9.09%
Variación en 3 años	-29.82%
Variación en 5 años	n/a
Variación desde la OPV	118.63%

Noticias y actualizaciones recientes

Artículo de análisis • Jun 21

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Biohaven (BHVN) drew investor attention after its stock rose 12.66% as the company outlined plans to start pivotal clinical studies for several cancer and autoimmune candidates in its pipeline. See our latest analysis for Biohaven. Looking beyond the latest jump, Biohaven’s share price return has been strong over shorter periods, with a 20.3% 7 day and 43.6% 30 day move. However, the 1 year total shareholder return declined 6.2%, which suggests recent momentum is rebuilding after a weaker...

Seeking Alpha • Jun 18

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

Summary Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomarker data for its protein degrader pipeline. The company is set to initiate pivotal studies for BHV-1300 in Graves' Disease and BHV-1400 in IgA Nephropathy in mid-2026, targeting large unmet markets. Phase 1b data show over 80% reduction in pathogenic TSHR-IgG1 for BHV-1300 and over 60% Gd-IgA1 reduction for BHV-1400, with safety advantages over competitors. With $351.8M cash as of March 2026 and additional equity capacity, the company is funded for at least one year, supporting multiple upcoming catalysts. Read the full article on Seeking Alpha

Recent updates

Artículo de análisis • Jun 21

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Seeking Alpha • Jun 18

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

Artículo de análisis • May 02

An Intrinsic Calculation For Biohaven Ltd. (NYSE:BHVN) Suggests It's 47% Undervalued

Key Insights Biohaven's estimated fair value is US$42.26 based on 2 Stage Free Cash Flow to Equity Current share price...

Seeking Alpha • Feb 28

Biohaven's Exciting Year Of Catalysts

Summary Following Pfizer's acquisition, Biohaven's valuation surged from $300M at $7/share to over $4B at $42/share under Vlad Coric's leadership. Despite the significant valuation increase, substantial upside remains due to Biohaven's promising later-stage clinical assets with key catalysts expected in 2025. The investment thesis hinges on the potential success of these clinical assets, which could drive further valuation growth. The current valuation rise is justified by the strategic leadership and promising pipeline, suggesting continued growth potential. Read the full article on Seeking Alpha

Seeking Alpha • Feb 11

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues

Summary Biohaven's pipeline is broad with multiple late stage molecules. Analysis based on Biohaven's 01/2025 J.P. Morgan Healthcare Conference Highlights and Presentation, Q3 2024 Earnings Release, and 10-Q. Biohaven's lead product's NDA is under review by the FDA. Article concludes with a "Hold" rating based on its hefty market cap and uncertain prospects. Read the full article on Seeking Alpha

Seeking Alpha • Nov 29

Biohaven's Revenue Path: SCA And Obesity Therapies

Summary Biohaven’s pipeline progression includes Troriluzole for spinocerebellar ataxia [SCA], which has shown a 50-70% reduction in disease progression over three years. BHV-2100, a non-opioid migraine treatment, targets unmet needs in a market affecting 40 million U.S. patients and 1 billion globally. Taldefgrobep Alfa, under investigation for SMA and obesity, demonstrated subgroup-specific motor function improvements and favorable safety in Phase 3 trials. Despite a $250 million equity raise, BHVN's cash burn of $141.9 million per quarter poses financial sustainability risks, making commercialization critical. Therefore, BHVN's positive clinical progress, high cash burn, and frequent equity raises make it a speculative buy. Read the full article on Seeking Alpha

Seeking Alpha • Oct 11

Biohaven: A Complicated Tale

Summary Biohaven's stock has surged despite past setbacks, driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies. The company is advancing a diverse pipeline, including myostatin inhibitor taldefgrobep alfa for SMA and obesity, and Kv7 ion channel activator BHV-7000 for epilepsy. Biohaven's strategic capital raises, and positive clinical data have rallied its stock, but future dilution risks remain if trials disappoint. An updated analysis of Biohaven follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Sep 23

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Summary Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with spinocerebellar ataxia; the Drug achieved 50% to 70% of slowing of disease progression over 3 years. With positive data on hand from the phase 3 study using troriluzole for patients with spinocerebellar ataxia, an NDA submission is planned for Q4 of 2024. Troriluzole is also being explored for patients with obsessive compulsive disorder in two phase 3 studies; Data from these studies are expected before the end of 2024 and the 1st half of 2025. Topline data from the phase 3 study using Taldefgrobep Alfa for SMA is expected 2nd half of 2024; the Drug is also expected to be initiated in a phase 2 study for obesity as well. Read the full article on Seeking Alpha

Seeking Alpha • Jul 26

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Summary Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight and fat loss, compared to that of GLP-1 alone. It is expected that the global obesity treatment market size is expected to be worth $38 billion by 2032. Read the full article on Seeking Alpha

Seeking Alpha • May 18

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

Summary Biohaven Ltd. is a spinout of Biohaven Pharmaceutical, focusing on developing drugs in the life sciences field. BHVN has three Phase 3 drug candidates: troriluzole for OCD, taldefgrobep alfa for SMA, and BHV-7000 for epilepsy and bipolar disorder. Also, the company has a diverse pipeline of drugs in various stages, including those targeting neurology, immunology, and oncology. Upcoming catalysts include FDA approval decisions and clinical trial results, which could significantly impact BHVN's stock performance. Despite the short cash runway, BHVN is a 'buy' due to its promising drug candidates and upcoming catalysts. Read the full article on Seeking Alpha

Artículo de análisis • Apr 06

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. By way of example, Biohaven...

Artículo de análisis • Mar 01

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biohaven fair value estimate is US$49.64 With US$48.14 share...

Seeking Alpha • Feb 28

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Summary Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, show promise and have blockbuster potential in treating epilepsy and immune-mediated diseases. Financially, with a cash runway extended to 20.7 months post-offering, Biohaven shows robust short-term health. Upgrading BHVN to "Buy" due to pipeline promise and market potential, despite competition risks and high cash burn. Read the full article on Seeking Alpha

Seeking Alpha • Dec 08

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Summary Today, we circle back on a promising biopharma concern called Biohaven Ltd., whose shares have had a significant rally in recent months. The company has a diverse pipeline of therapies for neurological and neuropsychiatric diseases, with a mixture of early and late-stage candidates. A portfolio review and analysis around Biohaven follow in the paragraphs below. Read the full article on Seeking Alpha

Artículo de análisis • Dec 04

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, Biohaven...

Seeking Alpha • Sep 27

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Summary Biohaven's stock surged nearly 30% following updates on its preclinical asset, the IgA degrader BHV-1300. The company's stock has risen more than 270% since its spinout from parent company Biohaven Pharmaceutical. Biohaven's preclinical pipeline includes assets targeting a wide range of central nervous system conditions and autoimmune diseases. As intriguing as today's data was, it does not necessarily support the buy case for Biohaven. Arguably, the data may have been released in response to promising IgG removal data released by Immunovant earlier this week. Time will tell, but I'm on the sidelines. Read the full article on Seeking Alpha

Seeking Alpha • Aug 28

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Summary Biohaven faces FDA rejection for troriluzole; explores further discussions and potential subgroup focus. Despite FDA setback, Biohaven maintains a strong cash position, diversified pipeline, and ongoing R&D efforts. Given current uncertainties and valuation, I recommend a "Sell" stance on Biohaven's stock. Read the full article on Seeking Alpha

Artículo de análisis • Jul 22

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Seeking Alpha • Jun 14

Biohaven: A Promising Investment In Innovative Neurological Therapies

Summary Biohaven offers a diverse portfolio of innovative drug development assets targeting various therapeutic areas, with a focus on neurodegenerative and neuroinflammatory conditions. The company's robust financials, diverse revenue streams, and recent performance results indicate a bright future and strong investment potential. Biohaven's innovative approaches and unique mechanisms of action set it apart from competitors, positioning the company as a compelling investment opportunity in the biopharmaceutical industry. Read the full article on Seeking Alpha

Seeking Alpha • Jun 06

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Summary Biohaven Ltd is a spinout of assets from Biohaven Pharmaceutical - just before the parent company was acquired by Pfizer last year for >$11bn. Much of the management team that developed Biohaven Pharmaceuticals' Nurtec migraine therapy, plus six other pipeline assets acquired by Pfizer, appear to be working at the new company. Biohaven Ltd shares have risen in value from ~$6, to >$20 - +265% in less than one year. An investor day presentation delivered last week appears to have generated significant upside momentum. An NDA has been submitted to the FDA for approval of a spinocerebellar ataxia Type 3 drug. At a market cap valuation of nearly $1.5bn and with no other near-term approval shots in play, Biohaven shares are not cheap, but the team is experienced. I would not be surprised if the upside momentum continues. Read the full article on Seeking Alpha

Artículo de análisis • Apr 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Feb 21

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

The U.S. Food and Drug Administration (FDA) granted fast track designation to Biohaven (NYSE:BHVN) medicine taldefgrobep alfa to treat spinal muscular atrophy (SMA). SMA is an inherited motor neuron disorder characterized by loss of nerve cells leading to muscle weakness over time. The company noted that taldefgrobep (also known as BHV2000) had previously received received orphan drug designation from the FDA to treat SMA. The drug is currently undergoing a phase 3 trial dubbed RESILIENT. Pfizer had acquired Biohaven Pharmaceuticals but a separate company Biohaven Ltd. was spunoff before the acquisition closed. BHVN +1.82% to $16.81 premarket Feb. 21

Rentabilidad de los accionistas

	BHVN	US Biotechs	Mercado US
7D	0.8%	4.1%	1.6%
1Y	9.1%	41.1%	18.6%

Rentabilidad vs. Industria: Los resultados de BHVN fueron inferiores a los de la industria US Biotechs, que obtuvo un rendimiento del 41.1% el año pasado.

Rentabilidad vs. Mercado: BHVN obtuvo unos resultados inferiores a los del mercado US, que fueron del 18.6% el año pasado.

Volatilidad de los precios

Is BHVN's price volatile compared to industry and market?
BHVN volatility
BHVN Average Weekly Movement	11.9%
Biotechs Industry Average Movement	10.3%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Precio estable de las acciones: El precio de las acciones de BHVN ha sido volátil durante los últimos 3 meses en comparación con el mercado US.

Volatilidad a lo largo del tiempo: La volatilidad semanal de BHVN(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2022	274	Vlad Coric	www.biohaven.com

Biohaven Ltd., empresa biofarmacéutica, se centra en el descubrimiento, desarrollo y comercialización de tratamientos para las áreas terapéuticas de inmunología, neurociencia y oncología en todo el mundo. Desarrolla el BHV-1300, que está en fase 2 de ensayo clínico para tratar la enfermedad de Graves y la artritis reumatoide; el BHV-1400 que está en fase 2 de ensayo clínico para tratar la nefropatía IgA; el BHV-1600, que está en fase 1 de ensayo clínico para el tratamiento de la cardiomiopatía periparto; BHV-8000, en fase 3 de ensayo clínico para el tratamiento de la enfermedad de Parkinson; Opakalim, en fase 3 de ensayo clínico para el tratamiento de la epilepsia focal; BHV-2100, en fase 2 de ensayo clínico para el tratamiento de los trastornos del dolor; y BHV-2000, en fase 2 de ensayo clínico para el tratamiento de la obesidad. La empresa también está desarrollando el BHV-1510, en fase 2 de ensayo clínico para el tratamiento de tumores epiteliales avanzados o metastásicos, y el BHV-1530, en fase 2 de ensayo clínico para el tratamiento del cáncer urotelial y otros tumores.

Resumen de fundamentos de Biohaven Ltd.

¿Cómo se comparan los beneficios e ingresos de Biohaven con su capitalización de mercado?
Estadísticas fundamentales de BHVN
Capitalización bursátil	US$2.40b
Beneficios(TTM)	-US$647.68m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-3.7x

Ratio precio-beneficio (PE)

¿Está BHVN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de BHVN
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$647.68m
Beneficios	-US$647.68m

Últimos beneficios comunicados

Mar 31, 2026

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-4.30
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	186.8%

¿Cómo se ha desempeñado BHVN a largo plazo?

Ver rendimiento histórico y comparativa

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/07/05 04:54
Precio de las acciones al final del día	2026/07/02 00:00
Beneficios	2026/03/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Biohaven Ltd. está cubierta por 23 analistas. 17 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Brian Skorney	Baird
William Pickering	Bernstein
Dina Ramadane	BofA Global Research

Biohaven (BHVN) Resumen de Acciones

Recompensas

Análisis de riesgos

Join community and earn perks

Competidores de Biohaven Ltd.

Kodiak Sciences

Vericel

Mineralys Therapeutics

Intellia Therapeutics

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Biohaven Advances Opakalim Epilepsy Study and Starts Phase 3 Graves’ Disease Trial

Biohaven Completes Enrollment In RISE3 Pivotal Phase 2/3 Study Evaluating Opakalim In Focal Epilepsy

Biohaven Ltd. Enrolls First Patient in Pivotal Phase 3 Trial of Bhv-1300 for Graves' Disease

Biohaven Begins Pivotal Oncology and Autoimmune Trials as Anticipation Builds

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

Recent updates

Biohaven Advances Opakalim Epilepsy Study and Starts Phase 3 Graves’ Disease Trial

Biohaven Completes Enrollment In RISE3 Pivotal Phase 2/3 Study Evaluating Opakalim In Focal Epilepsy

Biohaven Ltd. Enrolls First Patient in Pivotal Phase 3 Trial of Bhv-1300 for Graves' Disease

Biohaven Begins Pivotal Oncology and Autoimmune Trials as Anticipation Builds

Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares

Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations

Biohaven Begins First Human Trials of Oral BHV-8100 Targeting Metabolic and Immune Disorders

New minor risk - Share price stability

Biohaven Initiates First-In-Human Dosing of Oral Pkm2 Modulator Bhv-8100 Targeting Metabolic Restoration and Immunomodulation

Biohaven Reports Positive Clinical Biomarker and Patient Data for Bhv-1300 and Bhv-1400 in Graves' Disease and Iga Nephropathy

Biohaven Ltd. Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile

Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa

Biohaven Ltd., Annual General Meeting, Apr 28, 2026

New major risk - Financial position

Insufficient new directors

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs

New major risk - Share price stability

Biohaven Ltd. Presents Clinical Safety and Efficacy Data for BHV-1510

Price target decreased by 7.3% to US$39.07

New major risk - Shareholder dilution

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $175.000005 million.

New major risk - Negative shareholders equity

Price target decreased by 8.1% to US$42.13

Biohaven Ltd. Announces FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Pomerantz Law Firm Announces the Filing of A Class Action against Biohaven Ltd. and Certain Officers

Consensus revenue estimates decrease by 50%

Price target decreased by 7.7% to US$50.01

Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd

Consensus revenue estimates decrease by 22%

Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

Biohaven Ltd. Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and Fgfr3 Antibody Drug Conjugates Incorporating Novel Topoix Payload with Potential to Treat A Wide Variety of Tumors

New major risk - Financial position

Consensus revenue estimates fall by 38%

Fda Extends Pdufa Date of Biohaven's Troriluzole Nda for Rare Disease Spinocerebellar Ataxia

An Intrinsic Calculation For Biohaven Ltd. (NYSE:BHVN) Suggests It's 47% Undervalued

Consensus revenue estimates decrease by 14%

Biohaven Ltd. announced that it expects to receive $400 million in funding

New minor risk - Share price stability

Biohaven Ltd. Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

Biohaven Ltd., Annual General Meeting, May 05, 2025

Independent Director recently bought US$892k worth of stock

Biohaven Corporation Announces Acceptance and Priority Review by the United States Food and Drug Administration of the New Drug Application for Troriluzole in All-Genotype Spinocerebellar Ataxia

Biohaven's Exciting Year Of Catalysts

Biohaven Ltd. Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues

Independent Director recently bought US$1.0m worth of stock

Biohaven Ltd. Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested

Biohaven's Revenue Path: SCA And Obesity Therapies

Biohaven Ltd. Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

New major risk - Financial position

Biohaven: A Complicated Tale

Biohaven Ltd. has completed a Follow-on Equity Offering in the amount of $250.000005 million.

Biohaven Ltd. Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Price target increased by 9.2% to US$62.36

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Consensus EPS estimates fall by 21%

New major risk - Financial position

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer recently bought US$1.0m worth of stock

Independent Director recently bought US$996k worth of stock

Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day